The Oncotype DX Breast Recurrence Score® test can provide personalized insights for certain people with breast cancer, whose cancer is:​ Stage I, II, or IIIa​ HR ​ HER2-​ Each patient receives an individualized score to help them make more informed treatment choices.​ Learn more about the Oncotype DX® test: bit.ly/3AXOiBE | Until Everyone Knows

The Oncotype DX Breast Recurrence Score® test can help predict the chemotherapy benefit of a person with #BreastCancer.*​ Specifically, the test is for stage I-IIIA hormone receptor-positive, HER2-negative breast cancer. ​ Learn more about the Oncotype DX® test: https://bit.ly/41Js3Kr #CancerTreatment #CancerCare​ *Paik et al. J Clin Oncol. 2006;24(23):3726-3734; Albain et al. Lancet Oncol. 2010;11(1):55-65 | Until Everyone Knows

The Oncotype DX Breast Recurrence Score® test is the only test that has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer. And now, the National Comprehensive Cancer Network® (NCCN®) has updated its guidelines and recognized the Oncotype DX® test as the only assay that can be used for prediction of chemotherapy benefit in early-stage breast cancer patients with 1-3 positive axillary lymph nodes. Read more: https://exas.co/3dU3rEB | Exact

1.4K views · 46 reactions | In celebration of the 20th anniversary of Exact Sciences' Oncotype DX® test, we’re exploring its impact with the first patient who used it. | Katie Couric Media | Facebook